Can Homocysteine Levels Predict END in Acute Ischemic Stroke?
the MPR take:
While hyperhomocysteinemia as a risk factor for vascular disease is known, the relationship between homocysteine and the acute phase of stroke are unknown. This study sought to explore elevated serum homocysteine levels and early neurological deterioration (END) in patients with acute ischemic stroke. Using data from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, the researchers found that nearly 15% of patients worsened during the 7 day time frame and almost 70% of the END cases occurred within the first 24 hours after treatment. High levels (>10.3μmol/L) of serum homocysteine were found to be independent predictors for END.
READ FULL ARTICLE From stroke.ahajournals.org